Patient Guide: Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 153 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT06305754
Status: 🟢 Enrolling Now
Condition: Non-small Cell Lung Cancer (NSCLC)
Phase: PHASE3

Where You Can Participate

This study is available at 153 locations across the country.

Top locations include:
  • • Oakland, California
  • • Roseville, California
  • • San Francisco, California
  • • And 150 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) - Join Clinical Trial NCTNCT06305754

How to Join This Clinical Trial - NCTNCT06305754

Learn how to participate in this PHASE3 trial studying an investigational therapy for Non-small Cell Lung Cancer (NSCLC). This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Non-small Cell Lung Cancer (NSCLC). Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Non-small Cell Lung Cancer (NSCLC)
Treatment Being Tested
Investigational treatment
Study Phase
PHASE3 - Large-scale efficacy study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT06305754 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 153 locations. Find a study site near you:

Clinical Research Site

Oakland, California 94611 - United States

Status: RECRUITING

Clinical Research Site

Roseville, California 95661 - United States

Status: RECRUITING

Clinical Research Site

San Francisco, California 94115 - United States

Status: RECRUITING

Clinical Research Site

Santa Clara, California 95051 - United States

Status: RECRUITING

Clinical Research Site

Vallejo, California 94589 - United States

Status: RECRUITING

Clinical Research Site

Walnut Creek, California 94596 - United States

Status: RECRUITING

Clinical Research Site

Orange City, Florida 32763 - United States

Status: RECRUITING

Clinical Research Site

Marietta, Georgia 30060 - United States

Status: RECRUITING

Clinical Research Site

Ann Arbor, Michigan 48109 - United States

Status: RECRUITING

Clinical Research Site

Springfield, Missouri 65807 - United States

Status: RECRUITING

And 143 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE3 clinical trial for Non-small Cell Lung Cancer (NSCLC):

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships